Endocannabinoid System Offers New Targets for Migraine Patients Who Don't Respond to CGRP Drugs | Research

The takeaway

The endocannabinoid system intersects with CGRP signaling through multiple pathways, offering alternative therapeutic targets for migraine patients unresponsive to current anti-CGRP treatments.

Multi-target potential
The ECS modulates CGRP release through TRPV1, dopamine, serotonin, and ion channel pathways simultaneously

What the researchers found

The ECS modulates CGRP release and trigeminovascular signaling through TRPV1, D2 dopamine receptors, serotonergic, and ion channel pathways, offering multi-target therapeutic opportunities for CGRP-resistant migraine.

Why it matters

Up to 40-50% of migraine patients don't adequately respond to anti-CGRP therapies. Understanding how the ECS interacts with CGRP pathways could lead to new treatments for these patients.

How the study worked

Comprehensive narrative review mapping endocannabinoid component distribution in migraine-relevant brain regions and summarizing preclinical evidence for anti-nociceptive effects.

What this study cannot tell us

Preclinical evidence only; human translational data are very limited. Multi-target compounds add complexity and potential side effects. ECS modulation carries regulatory challenges.

How to read the evidence

Comprehensive preclinical review with strong mechanistic rationale but limited human translational data.

When this study was published

Published in 2025, integrating the latest understanding of ECS-CGRP crosstalk in migraine.

The bigger picture

This work bridges the neuropeptide (CGRP) and endocannabinoid fields, showing they are not separate systems but interacting networks that could be targeted together for better migraine treatment.

Questions still open

Could combined ECS modulation and anti-CGRP therapy help treatment-resistant migraine patients?
Will endocannabinoid-degrading enzyme inhibitors prove effective in human migraine trials?
Can ECS-mediated glymphatic clearance contribute to migraine prevention?

Common questions

What is the endocannabinoid system and how does it relate to migraines?

The ECS is a natural signaling system in the body that regulates pain, inflammation, and nerve function. It interacts with CGRP—the neuropeptide targeted by migraine drugs—through multiple pathways, offering additional treatment possibilities.

Could this help if CGRP drugs don't work for my migraines?

Potentially. By targeting the endocannabinoid system alongside or instead of CGRP, researchers hope to help the many migraine patients who don't respond to current anti-CGRP medications. However, these approaches are still in preclinical development.

Read the original research

Overlapping pathways of migraine and the endocannabinoid system: Potential therapeutic targets.

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, e00833

View on PubMed ↗Publisher’s paper ↗

Citation

Della Pietra, Adriana; Russo, Andrew F. (2026). Overlapping pathways of migraine and the endocannabinoid system: Potential therapeutic targets.. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, e00833. https://doi.org/10.1016/j.neurot.2026.e00833